Boston Scientific Corp. upped the ante for heart devices maker Guidant Corp. again Tuesday, raising its bid to $80 a share, or $27 billion.
The new offer from the Natick, Mass.-based company makes its bid worth about $3 billion more than one from Johnson & Johnson, whose rival $24 billion offer the Guidant board accepted last week.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
